BUY Biocon Ltd — Rajesh Agarwal, AUM Capital

Entry₹411.55Inferred
Target₹500
Total upside +21.49%
Stop lossNot given
CMP₹351.85h ago
Active-14.52%+42.13%upside left 8 mo left

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 30 Oct, 9:24 pm IST
38 supporting13 neutral4 opposing
Supports the BUY call (38)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·30 Oct · today

6 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·28 Oct · 2d ago

Biocon gets additional global market entry for Yesintek to treat autoimmune diseases

NewsCnbc-Tv18·26 Oct · 4d ago

(opens in new tab)

Biocon settles licence agreement with Genetech for cancer treatment drug — Check earliest secured launch dates

NewsCnbc-Tv18·14 Oct · 2w ago

(opens in new tab)

1 advisor has an active short-term BUY call on this stock

Advisor consensus · adjacent horizon·19 Sept · 1mo ago

Weighs against the BUY call (4)

1 advisor has an active short-term SELL call on this stock

Advisor consensus · adjacent horizon·9 Oct · 3w ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.